Biodegradable polymers for Injectables and Drug Delivery Devices

PURASORB® polymers are suitable for formulating injectable and implantable drug delivery devices for both veterinary and human use. They are successfully applied in a wide range of controlled release systems for oncology, CNS, pain management as well as many other indications.

Versatility you can rely on 

PURASORB polymers are used as resorbable excipients in the formulation of controlled release systems. Using PURASORB in your controlled release formulation enables you to deliver therapeutic levels of a drug to patients over days, weeks, months, with a single injection.polymersomes.

Our polymers can be used to provide a well-established and patient compliant drug delivery solution both for new API’s as well as generic controlled release formulations.

PEG di- and tri-block copolymers

Corbion Biomaterials manufactures high quality polyethylene glycol copolymers. Our DL-lactide / PEG block copolymers (AB and ABA) and DL-lactide/glycolide PEG block copolymers (AB and ABA) are available from small non-GMP laboratory scale to commercial scale in GMP.

Maximum flexibility 

Our resorbable polymers allow for maximum flexibility in processing technologies, ranging from extrusion and solvent processing to spray drying.


The properties of our polymers can be tuned to the desired release time and hydrophilicity to facilitate the delivery of a broad range of actives, ranging from small molecules to peptides and proteins.


PURASORB resorbable polymers for controlled release systems are commercially available in our PDLG (Poly DL-lactide/glycolide) and PDL (Poly DL-lactides) families. These families of polymers have been used commercially in medical and pharmaceutical applications for many years.

Quality and consistency time after time

Corbion Biomaterials works to the highest quality standards based on ICHQ7 guidelines,

with DMF and MAF files maintained at the FDA. Our commitment is to ensure a high quality, reliable supply of resorbable polymers that meets your requirements now and into the future. We invest continually in our business to guarantee this commitment.

Risk management and dual sourcing

Our dedicated GMP production facility in Europe incorporates proven, large scale technology that enables us to produce a wide range of batch sizes from 5 to over 100 kg with outstanding batch-to-batch consistency. Our GMP production facility in the United States extends and strengthens our manufacturing base even further, bringing the additional reassurance of global supply continuity and reflecting Corbion’s commitment to the Medical Biomaterials domain.

Go to article: Home | A new era of buyers clubsGo to article: TSS ABGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Capsugel Company InsightGo to article: The pharma industry briefingGo to article: ICCI Company InsightGo to article: ICCIGo to article: Corbion PuracGo to article: Real world data: improving clinical trial outcomesGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: Understanding allergic reactions: chronicling the work of Dr Teruko IshizakaGo to article: Scandinavian HealthGo to article: Moehs Iberica SLGo to article: Swiss WorldCargoGo to article: Buyers’ clubs: the first step toward universal UK access to Orkambi?Go to article: TSS Company InsightGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CRO GmbHGo to article: Prescription dread: measuring psychiatric drugs against the alternativesGo to article: BEAGo to article: ZenatekGo to article: PfanstiehlGo to article: Herd health: agriculture’s role in the global AMR crisisGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Hapa Company InsightGo to article: ConcePTION: tackling the unknowns of medication in pregnancyGo to article: AEB Company Insight Go to article: AEBGo to article: Pfeiffer VacuumGo to article: From start-ups to the SIX Swiss Exchange – a Swiss success storyGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Cancer drug discovery: unravelling the mysteries of halichondrinGo to article: Centaur Clinical | Company InsightGo to article: IDMP is back: what next?Go to article: Charles Ischi Go to article: Adhesives ResearchGo to article: Emirates SkyCargoGo to article: Global labelling management: why does it continue to cause problems?Go to article: B&W TekGo to article: EventsGo to article: Dali Medical devicesGo to article: Spirax Sarco Company InsightGo to article: Spirax SarcoGo to article: Centaur ClinicalGo to article: Next issueGo to article: AralabGo to article: Baxter